The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α

Virology

Volumn 259, Issue 2, 1999, Pages 305-313

  Barnard, Paula ^a   McMillan, Nigel A J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ONCOPROTEIN; RETINOBLASTOMA PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INHIBITION; CELL CULTURE; GENE INDUCTION; GENE REPRESSION; GENE TRANSLOCATION; IMMUNOTHERAPY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; WART VIRUS;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPOVAVIRIDAE;

EID: 0033526860     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9771     Document Type: Article

References (32)

1. Anderson K. P., Fennie E. H. Adenovirus early region 1A modulation of interferon antiviral activity. J. Virol. 61:1987;787-795.
2. Antinore M. J., Birrer M. J., Patel D., Nader L., McCance D. J. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 15:1996;1950-1960.
3. Arany I., Goel A., Tyring S. K. Interferon response depends on viral transcription in human papillomavirus-containing lesions. Anticancer Res. 15:1995;2865-2870.
4. Armstrong D. K., Maw R. D., Dinsmore W. W., Blaakaer J., Correa M. A., Falk L., Ferenczy A. S., Fortier M., Frazer I., Law C., Moller B. M., Oyakawa N. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Genitourin. Med. 72:1996;103-107.
5. Bluyssen H. A. R., Muzaffar R., Vlieststra R. J., van der Made A. C. J., Leung S., Stark G. R., Kerr I. M., Trapman J., Levy D. E. Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc. Natl. Acad. Sci. USA. 92:1995;5645-5649.
6. Carroll K., Elroy-Stein O., Moss B., Jagus R. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase. J. Biol. Chem. 268:1993;12837-12842.
7. Chang H. W., Watson J. C., Jacobs B. L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 89:1992;4825-4829.
8. Darnell J. E. Jr., Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1994;1415-1421.
9. Dyson N., Guida P., Munger K., Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66:1992;6893-6902.
10. Frazer I. H., McMillan N. A. J. Papillomatosis and condylomata acuminata. Stuart-Harris R., Penny R. D. Clinical Applications of the Interferons. 1997;79-90 Chapman and Hall Medical, London.
11. Gutch M. J., Reich N. C. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc. Natl. Acad. Sci. USA. 88:1991;7913-7917.
12. John J., McKendry R., Pellegrini S., Flavell D., Kerr I. M., Stark G. R. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol. Cell. Biol. 11:1991;4189-4195.
13. Kalvakolanu D. V. R., Bandyopadhyay S. K., Harter M. L., Sen G. C. Inhibition of interferon-inducible gene expression by adenoviral E1A proteins: Block in transcriptional complex formation. Proc. Natl. Acad. Sci. USA. 88:1991;7459-7463.
14. Kaur P., McDougall J. K. Characterization of primary human keratinocytes transformed by human papillomavirus type 18. J. Virol. 62:1988;1917-1924.
15. Kuhen K. L., Samuel C. E. Isolation of the interferon-inducible RNA-dependent protein kinase Pkr promoter and identification of a novel DNA element within the 5′-flanking region of human and mouse Pkr genes. Virology. 227:1997;119-130.
16. Leonard G. T., Sen G. C. Effects of adenovirus E1A protein on interferon-signaling. Virology. 224:1996;25-33.
17. Leonard G. T., Sen G. C. Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. J. Virol. 71:1997;5095-5101.
18. Lew D. J., Decker T., Strehlow I., Darnell J. E. Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons. Mol. Cell. Biol. 11:1991;182-191.
19. Linge C., Gewert D., Rossmann C., Bishop J. A., Crowe J. S. Interferon system defects in human malignant melenoma. Cancer Res. 55:1995;4099-4104.
20. Liptákova H., Kontsekova E., Alcami A., Smith G. L., Kontsek P. Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha1 and IFN-alpha2. Virology. 232:1997;86-90.
21. Miyakoshi J., Dobler K. D., Allalunis-Turner J., McKean J. D., Petruk K., Allen P. B., Aronyk K. N., Weir B., Huyser-Wierenga D., Fulton D. Absence of IFNA and IFNB genes from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferons. Cancer Res. 50:1990;278-283.
22. Moro A., Calixto A., Suarez E., Arana M. J., Perea S. E. Differential expression of the p27Kip1 mRNA in IFN-sensitive and resistant cell lines. Biochem. Biophys. Res. Commun. 245:1998;752-756.
23. Perea S. E., Lopez-Ocejo O., von Gabain A., Arana M. d. J. Human papillomavirus type-16 (HPV-16) major transforming proteins functionally interact with interferon signaling mechanisms. Int. J. Oncol. 11:1997;169-173.
24. Petricoin E. 3rd, David M., Fang H., Grimley P., Larner A. C., Vande Pol S. Human cancer cell lines express a negative transcriptional regulator of the interferon regulatory factor family of DNA binding proteins. Mol. Cell. Biol. 14:1994;1477-1486.
25. Ronco L. V., Karpova A. Y., Vidal M., Howley P. M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:1998;2061-2072.
26. Schneider A., Papendick U., Gissmann L., De Villiers E. M. Interferon treatment of human genital papillomavirus infection: Importance of viral type. Int. J. Cancer. 40:1987;610-614.
27. Stark G. R., Kerr I. M. Interferon-dependent signaling pathways: DNA elements, transcription factors, mutations and effects of viral proteins. J. Interferon Res. 12:1992;147-151.
28. Vilcek J., Sen G. C. Interferons and other cytokines. Fields B. N., Knipe D. M., Howley P. M. Fields Virology. 1996;Lippincott-Raven, Philadelphia.
29. Willman C. L., Sever C. E., Pallavicini M. G., Harada H., Tanaka N., Slovak M. L., Yamamoto H., Harada K., Meeker T. C., List A. F. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 259:1993;968-971.
30. Wong L. H., Krauer K. G., Hatzinisiriou I., Estcourt M. J., Hersey P., Tam N. D., Edmondson S., Devenish R. J., Ralph S. J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J. Biol. Chem. 272:1997;28779-28785.
31. Woodworth C. D., Lichti U., Simpson S., Evans C. H., DiPaolo J. A. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res. 52:1992;456-463.
32. zur Hausen H., de Villiers E. M. Human papillomaviruses. Annu. Rev. Microbiol. 48:1994;427-447.